Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($1.27), $0.07 worse than the analyst estimate of ($1.20). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $4.61 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.